Stocks · News reference
XOS: 140% | Xos shares are trading higher after the company announced that it has been awarded a prototype Other Transaction Agreement by the United States Air Force to develop and deliver a deployable mobile charging
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,
Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our
Filed: 2026-09-08 AccNo: 0001193125-26-385331 Size: 147 KB Item 1.01: Entry into a Material Definitive Agreement
Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.
Nine of 11 sectors are higher in Tuesday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Utilities well ahead of the next group.
Jim Cramer cheers "Interest rates can fall, too!!" as CME FedWatch data shows the odds of an October Fed rate hike dropping to just 22%.